GeneSystem Co

GeneSystem Co FCF Yield

The Free Cash Flow Yield of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is -21.51 %. In the previous year, Free Cash Flow Yield was -22.94 % — a change of -6.24% (higher).

FCF Yield

-21.51 %

YoY

-6.24%

Last updated:

Free Cash Flow Yield of GeneSystem Co is 2025 -21.51 % . Free Cash Flow Yield of GeneSystem Co was 2024 -22.94 % . It decreases by -6.24% higher compared to the previous year.

The GeneSystem Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-5.51 KRW
Jan 1, 2019
-7.12 KRW
Jan 1, 2020
-6.21 KRW
Jan 1, 2021
1.97 KRW
Jan 1, 2022
-19.83 KRW
Jan 1, 2023
-24.53 KRW
Jan 1, 2024
-22.94 KRW
Jan 1, 2025
-21.51 KRW
The GeneSystem Co FCF Yield history
YEARFCF YieldYoY
-21.51 %-6.24%
-22.94 %-6.47%
-24.53 %+23.67%
-19.83 %-1,105.70%
1.97 %-131.73%
-6.21 %-12.77%
-7.12 %+29.27%
-5.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Free Cash Flow Yield of GeneSystem Co is -21.51 % in 2025.

Free Cash Flow Yield of GeneSystem Co changed from -22.94 % to -21.51 %, representing a -6.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GeneSystem Co

All Key Metrics — GeneSystem Co